Genentech, Inc.

F. Hoffmann-la Roche Ag

Teemu T Junttila

Allen J Ebens

Christoph Spiess

Ji Li

Diego Ellerman

Mark S Dennis

Paul J Carter

Robert F Kelley

Xiaocheng Chen

Isidro Hotzel

Mary A Mathieu

Danielle Dicara

Andrew G Polson

Justin M Scheer

Jo-Anne Hongo

Meredith C Hazen

Bryan Irving

Liping L Sun

Twyla Noelle Lombana

Jennifer W Johnston

Dionysos Slaga

Justin Scheer

Paul Carter

The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.

Bispecific antigen-binding molecules and methods of use

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

Humanized and affinity matured antibodies to FcRH5 and methods of use

The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

Anti-CD3 antibodies and methods of use

The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.

Anti-FCRH5 antibodies

Anti-FcRH5 antibodies

Growing community of inventors

San Mateo, CA, United States of America

Teemu T Junttila